Phase 3 Study Results Bring Hope for Children with Primary Hyperoxaluria Type 1  
source: pixabay.com

Phase 3 Study Results Bring Hope for Children with Primary Hyperoxaluria Type 1  

  According to a recent article in BioSpace, young children and infants who have been diagnosed with primary hyperoxaluria type 1 (PH1) are often faced with the use of gastrostomy…

Continue Reading Phase 3 Study Results Bring Hope for Children with Primary Hyperoxaluria Type 1  
An Experimental Treatment for Primary Hyperoxaluria has Earned Rare Pediatric Disease Designation
source: pixabay.com

An Experimental Treatment for Primary Hyperoxaluria has Earned Rare Pediatric Disease Designation

According to a story from BioSpace, the biopharmaceutical company Dicerna Therapeutics, Inc. has announced recently that the US Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to…

Continue Reading An Experimental Treatment for Primary Hyperoxaluria has Earned Rare Pediatric Disease Designation

Alnylam Seeks FDA Approval for First Treatment of Primary Hyperoxaluria Type 1

Copyscape score: 2% Alnylam has recently completed the third phase of their clinical trial of lumasiran, which was created for the treatment of primary hyperoxaluria type 1 (PH1). While they…

Continue Reading Alnylam Seeks FDA Approval for First Treatment of Primary Hyperoxaluria Type 1

Watch: Pharma Company Produces Cartoon Series for PH1 Awareness among Kids 

Alnylam Pharmaceuticals has developed and produced a cartoon series aimed at educating people -- especially young people -- about the pediatric rare disease primary hyperoxaluria type 1 (PH1). The campaign…

Continue Reading Watch: Pharma Company Produces Cartoon Series for PH1 Awareness among Kids 

Pediatric Clinical Trial Initiated for Primary Hyperoxaluria Type 1!

Alnylam Pharmaceuticals has been developing lumasiran as a potential treatment for primary hyperoxaluria type 1 (PH1). This investigation began with ILLUMINATE-A, a clinical trial whose results should be announced by…

Continue Reading Pediatric Clinical Trial Initiated for Primary Hyperoxaluria Type 1!
New Updates on Studies of Lumasiran in Patients With Primary Hyperoxaluria Type 1
jniittymaa0 / Pixabay

New Updates on Studies of Lumasiran in Patients With Primary Hyperoxaluria Type 1

Alnylam has provided updates about their programs for patients with primary hyperoxaluria type 1 (PH1), a rare condition that affects the kidneys and bladder. As part of their Alnylam Act® program,…

Continue Reading New Updates on Studies of Lumasiran in Patients With Primary Hyperoxaluria Type 1
Proof of Concept Data Released for Potential Primary Hyperoxaluria Treatment
jarmoluk / Pixabay

Proof of Concept Data Released for Potential Primary Hyperoxaluria Treatment

According to a story from BioPortfolio, the drug development company Dicerna Pharmaceuticals recently announced the release of proof of concept data in its Phase I trial testing the company's experimental…

Continue Reading Proof of Concept Data Released for Potential Primary Hyperoxaluria Treatment
Study Shows Encouraging Results For an Experimental Treatment For Primary Hyperoxaluria Type 1
mohamed_hassan / Pixabay

Study Shows Encouraging Results For an Experimental Treatment For Primary Hyperoxaluria Type 1

A phase 1/2 study of the drug lumasiran for the treatment of primary hyperoxaluria Type 1 has produced encouraging results, reports Alnylam Pharmaceuticals. The full article can be read here,…

Continue Reading Study Shows Encouraging Results For an Experimental Treatment For Primary Hyperoxaluria Type 1
A Study of an Investigational Drug For Primary Hyperoxaluria Has Dosed its First Patient
Source: Pixabay

A Study of an Investigational Drug For Primary Hyperoxaluria Has Dosed its First Patient

Dicerna Pharmaceuticals has dosed the first patient with primary hyperoxaluria in Group B of a clinical trial of the investigational drug DCR-PHXC. Dicerna has also announced that DCR-PHXC has just…

Continue Reading A Study of an Investigational Drug For Primary Hyperoxaluria Has Dosed its First Patient
Close Menu